CN107073089A - 用于癌症疫苗的包被的溶瘤腺病毒 - Google Patents

用于癌症疫苗的包被的溶瘤腺病毒 Download PDF

Info

Publication number
CN107073089A
CN107073089A CN201580026994.7A CN201580026994A CN107073089A CN 107073089 A CN107073089 A CN 107073089A CN 201580026994 A CN201580026994 A CN 201580026994A CN 107073089 A CN107073089 A CN 107073089A
Authority
CN
China
Prior art keywords
cancer
polypeptide
adenovirus
specific
adenovirus vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580026994.7A
Other languages
English (en)
Chinese (zh)
Inventor
文森佐·史汝乐
马库斯·瓦哈科斯凯拉
马里·黑尔维尼
克里斯蒂安·卡帕索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Helsinki
Original Assignee
University of Helsinki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Helsinki filed Critical University of Helsinki
Priority to CN202511457024.4A priority Critical patent/CN121313807A/zh
Publication of CN107073089A publication Critical patent/CN107073089A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
CN201580026994.7A 2014-05-19 2015-05-18 用于癌症疫苗的包被的溶瘤腺病毒 Pending CN107073089A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511457024.4A CN121313807A (zh) 2014-05-19 2015-05-18 用于癌症疫苗的包被的溶瘤腺病毒

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20145449 2014-05-19
FI20145449 2014-05-19
PCT/EP2015/060903 WO2015177098A2 (en) 2014-05-19 2015-05-18 Modified adenoviruses for cancer vaccines development

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511457024.4A Division CN121313807A (zh) 2014-05-19 2015-05-18 用于癌症疫苗的包被的溶瘤腺病毒

Publications (1)

Publication Number Publication Date
CN107073089A true CN107073089A (zh) 2017-08-18

Family

ID=53189815

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580026994.7A Pending CN107073089A (zh) 2014-05-19 2015-05-18 用于癌症疫苗的包被的溶瘤腺病毒
CN202511457024.4A Pending CN121313807A (zh) 2014-05-19 2015-05-18 用于癌症疫苗的包被的溶瘤腺病毒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511457024.4A Pending CN121313807A (zh) 2014-05-19 2015-05-18 用于癌症疫苗的包被的溶瘤腺病毒

Country Status (12)

Country Link
US (2) US10799568B2 (enExample)
EP (1) EP3145537B1 (enExample)
JP (3) JP6705755B2 (enExample)
KR (1) KR102437072B1 (enExample)
CN (2) CN107073089A (enExample)
AU (2) AU2015263286B2 (enExample)
CA (1) CA2949174A1 (enExample)
ES (1) ES2714921T3 (enExample)
NZ (1) NZ726112A (enExample)
RU (1) RU2695375C2 (enExample)
WO (1) WO2015177098A2 (enExample)
ZA (1) ZA201607715B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289920A (zh) * 2015-10-12 2018-07-17 汉阳大学校产学协力团 用于基因转移和基因治疗的腺病毒复合物
WO2020192684A1 (zh) * 2019-03-27 2020-10-01 杭州康万达医药科技有限公司 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用
CN112118864A (zh) * 2018-03-21 2020-12-22 瓦洛治疗公司 经修饰的溶瘤腺病毒
CN112135902A (zh) * 2018-03-21 2020-12-25 瓦洛治疗公司 癌症疗法
CN114302740A (zh) * 2019-05-24 2022-04-08 瓦洛治疗公司 病毒载体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
JP6705755B2 (ja) * 2014-05-19 2020-06-03 バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 癌ワクチン開発のための改変アデノウイルス
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3675902A4 (en) 2017-08-28 2021-06-23 Board of Trustees of Michigan State University COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND INFECTION USING BACTERIOPHAGE AND THEIR MUTANTS
US20200397892A1 (en) * 2018-02-22 2020-12-24 Turnstone Limited Partnership Oncolytic viruses as adjuvants
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
US20230144068A1 (en) * 2020-03-31 2023-05-11 Kaneka Corporation Method for preparing modified vector and method for modifying vector
GB202006760D0 (en) 2020-05-07 2020-06-24 Univ Helsinki Bioinformatics
GB202013834D0 (en) 2020-09-03 2020-10-21 Valo Therapeutics Oy PeptiVAX therapy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294517A (zh) * 1997-11-14 2001-05-09 欧洲细胞技术有限公司 具有合成可变区和修饰特异性的免疫球蛋白分子
CN1314948A (zh) * 1998-08-27 2001-09-26 阿文蒂斯药物股份有限公司 用于递送异源基因的定向腺病毒载体
WO2002020724A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Adenoviral targeting and manipulation of immune system response using targeting peptides
CN1368885A (zh) * 1999-05-06 2002-09-11 威克福雷大学 用于鉴定引起免疫反应的抗原的组合物和方法
CN1665921A (zh) * 2002-04-30 2005-09-07 艾维亚医药/生物技术有限公司 用于免疫治疗的腺病毒载体
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
CN103221423A (zh) * 2010-09-24 2013-07-24 昂克斯治疗有限公司 溶瘤腺病毒载体及与其相关的方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569426B2 (en) * 1997-04-03 2003-05-27 Genzyme Corporation Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
AU2001234981A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
AU2002308713B2 (en) * 2001-06-22 2008-05-15 The Trustees Of The University Of Pennsylvania Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
US20040102382A1 (en) * 2002-11-27 2004-05-27 Transgene, S.A. Targeting peptides
US7776322B2 (en) * 2004-08-16 2010-08-17 Stefan Kochanek Modified viral vector particles
US20060045881A1 (en) * 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
EP1985708B1 (en) 2007-04-27 2015-04-15 Universität Rostock Selective targeting of viruses to neural precursor cells
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
ES2335077B1 (es) 2008-12-30 2011-02-02 Instituto Aragones De Ciencias De La Salud Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores.
RU2013118723A (ru) * 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
US20140140962A1 (en) * 2011-04-29 2014-05-22 The Research Foundation Of State University Of New York Viruses modified with unnatural moieties and methods of use thereof
US20120308660A1 (en) * 2011-06-02 2012-12-06 Paxvax, Inc. Nanocoatings for biological materials
JP6705755B2 (ja) * 2014-05-19 2020-06-03 バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 癌ワクチン開発のための改変アデノウイルス

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294517A (zh) * 1997-11-14 2001-05-09 欧洲细胞技术有限公司 具有合成可变区和修饰特异性的免疫球蛋白分子
CN1314948A (zh) * 1998-08-27 2001-09-26 阿文蒂斯药物股份有限公司 用于递送异源基因的定向腺病毒载体
CN1368885A (zh) * 1999-05-06 2002-09-11 威克福雷大学 用于鉴定引起免疫反应的抗原的组合物和方法
WO2002020724A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Adenoviral targeting and manipulation of immune system response using targeting peptides
CN1665921A (zh) * 2002-04-30 2005-09-07 艾维亚医药/生物技术有限公司 用于免疫治疗的腺病毒载体
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
CN103221423A (zh) * 2010-09-24 2013-07-24 昂克斯治疗有限公司 溶瘤腺病毒载体及与其相关的方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RAVI SINGH等: "Designer adenoviruses for nanomedicine and nanodiagnostics", 《TRENDS IN BIOTECHNOLOGY》 *
刘旭等: "溶瘤腺病毒在肿瘤靶向治疗中的研究进展", 《现代生物医学进展》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289920A (zh) * 2015-10-12 2018-07-17 汉阳大学校产学协力团 用于基因转移和基因治疗的腺病毒复合物
CN112118864A (zh) * 2018-03-21 2020-12-22 瓦洛治疗公司 经修饰的溶瘤腺病毒
CN112135902A (zh) * 2018-03-21 2020-12-25 瓦洛治疗公司 癌症疗法
WO2020192684A1 (zh) * 2019-03-27 2020-10-01 杭州康万达医药科技有限公司 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用
CN114302740A (zh) * 2019-05-24 2022-04-08 瓦洛治疗公司 病毒载体

Also Published As

Publication number Publication date
RU2016147003A (ru) 2018-06-20
EP3145537A2 (en) 2017-03-29
NZ764519A (en) 2021-08-27
JP7657028B2 (ja) 2025-04-04
US11730798B2 (en) 2023-08-22
NZ726112A (en) 2021-07-30
ES2714921T3 (es) 2019-05-30
US10799568B2 (en) 2020-10-13
CA2949174A1 (en) 2015-11-26
EP3145537B1 (en) 2018-12-12
ZA201607715B (en) 2017-09-27
AU2015263286B2 (en) 2020-03-12
BR112016026745A2 (pt) 2017-12-12
WO2015177098A2 (en) 2015-11-26
US20170080069A1 (en) 2017-03-23
AU2015263286A1 (en) 2016-11-24
JP6705755B2 (ja) 2020-06-03
RU2695375C2 (ru) 2019-07-23
KR102437072B1 (ko) 2022-08-26
AU2020203816B2 (en) 2021-11-18
CN121313807A (zh) 2026-01-13
JP2017522267A (ja) 2017-08-10
JP7030867B2 (ja) 2022-03-07
WO2015177098A3 (en) 2016-02-18
RU2016147003A3 (enExample) 2018-11-08
JP2020110165A (ja) 2020-07-27
US20210100883A1 (en) 2021-04-08
JP2020143128A (ja) 2020-09-10
AU2020203816A1 (en) 2020-07-02
KR20170012326A (ko) 2017-02-02

Similar Documents

Publication Publication Date Title
JP7657028B2 (ja) 癌ワクチン開発のための改変アデノウイルス
JP7641005B2 (ja) コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
US10617729B2 (en) Multitargeting onocolytic adenovirus, methods of use, and methods of making
JP2020531053A (ja) 疾患の予防および／または治療における使用のためのワクチン
KR20200135987A (ko) 암 치료요법
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
KR20220116191A (ko) 4-1bbl 아쥬반트화 재조합 변형 백시니아 바이러스 앙카라 (mva)의 의약적 용도
EP2869828B1 (en) Vault immunotherapy
WO2011017107A2 (en) Microbubble assisted viral delivery
US20260061044A1 (en) Mutated Influenza Virus, Pharmaceutical Composition, and Use
US20230062122A1 (en) Modified adenoviruses for infectious disease vaccine development
WO2021036245A1 (zh) 携带安全开关并靶向EGFRvⅢ的嵌合抗原受体T细胞及其制备方法和应用
HK1235686B (en) Coated oncolytic adenoviruses for cancer vaccines
HK1235686A1 (en) Coated oncolytic adenoviruses for cancer vaccines
BR112016026745B1 (pt) Uso de um vetor adenoviral oncolítico, vetor adenoviral oncolítico, método para modificação da cápside de um adenovírus, uso de polipeptídeos modificados por polilisina, e, composição farmacêutica
NZ764519B2 (en) Coated adenoviruses for immunotherapy
AU2020378088A1 (en) Replication-enhanced oncolytic adenoviruses
WO2021036244A1 (zh) 携带安全开关并靶向Her2的嵌合抗原受体T细胞及其制备方法和应用
BR112020019322B1 (pt) Adenovírus modificado, composição farmacêutica compreendendo o mesmo e uso
CN108289920A (zh) 用于基因转移和基因治疗的腺病毒复合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170818

RJ01 Rejection of invention patent application after publication